| BUSINESS DEVELOPMENT |
|
Sun Pharma is an international speciality pharma company. We have a significant presence in the US through our subsidiary Caraco. In the rest of world markets, we have a strong ground network of 400 committed field force in 30 countries, with over 1000 products registered and marketed. We have 2500-person strong sales team in India distributing through 2000 stockists, We are now at a stage of rapid growth across geographies spanning Russia and CIS countries, China and South east Asia, Africa and Latin America, where we are rapidly emerging as a branded generic company of choice.
In India, we are among the largest pharmaceutical companies and command a 3.3% market share.( ORG IMS Stockist Audit, Aug’07). In India, we market about 500 products through 17 speciality marketing divisions that are built around chronic therapy areas. Typically, every year we introduce 25 -30 new products. All of these are developed in- house supported by strong bulk synthesis, formulation development, bioequivalence and regulatory teams. CMARC ( A prescription audit agency ) has ranked us as no 1 in key chronic therapy areas of Neuro-Psychiatry, Cardiology, Diabetology, Gatsroenterology and Ophthalmology. We rank among the top 5 companies for Respiratory, Pain, Cancer and Gynecology. |
|
| In-Licensing |
|
We look at partnering and collaborating as an important strategic approach that will complement our growth in India and international markets. Our constant need is to add to our specialty product portfolio for prescription leadership in India. We also seek to strengthen our presence, with a complete basket of speciality products, in Russia and CIS countries, China and South East Asia, Africa, Brazil and Mexico.
We are currently interested in in-licensing products that are already marketed or are in late stage clinical development in our key therapy areas. We seek products that leverage our core strengths and complement our existing product portfolio in the following therapy areas: |
| |
 |
CNS disorders |
|
Oncology |
|
Pain |
|
Allergy, Asthma and Inflammation |
|
Gynecologicals |
|
|
Biosimilar products and new products based on recombinant/humanized monoclonal antibody technology that find use in these therapy areas is one of our key requirements. |
|
We seek to establish a long term, mutually rewarding relationship based on on exclusive marketing rights business model for the above listed geographies, as well as co-marketing or strategic alliances for co-development including clinical trials of products for necessary regulatory approvals. |
|
Out-licensing |
|
Our formulation development expertise enables us to develop complex generic products which are bioequivalent, sustained release oral dosage forms and long acting injectable depot formulations.
We offer a range of dosage forms for oral, injectable, topical and transdermal routes developed through non-infringing routes and/or patented routes in the following therapeutic areas:
|
| |
|
CVS |
|
CNS |
|
Pain |
|
Cancer |
|
Gynecologicals |
|
Allergy, Asthma other respiratory diseases |
|
|
Our Organic synthesis team develops highly complex bulk actives like Peptides, Hormones, Steroids, Anticancer drugs and Cephalosporins through non-infringing routes and/or patented routes. We offer over 150 bulk actives manufactured at USFDA/UK MHRA approved sites .
We seek out-licensing opportunities for our speciality generics, super generics, and bulk drugs for global markets. |
|
|
|
 |
|
|
|
|
|
